Toxicology
Annals of Medicine
In the Toxicology section of Annals of Medicine we consider for publication the latest advances in:
| Drug Metabolism | Pharmacokinetics | Pre-clinical Toxicology |
| Safety Assessment | Toxicology |
In addition, this section considers manuscripts that include research on biologic drugs, pharmaceuticals, cell and gene therapy products.
Annals of Medicine
Q1 Rank
Two-Year Impact Factor 3.243
Five-Year Impact Factor 3.840
MEDLINE® Indexed
CiteScore 5.70
Meet the Section Editor
Rakesh Dixit, CEO & President, Bionavigen, LLC
Rakesh Dixit is President & CEO at BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in drug hunting, advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. He conducted extensive graduate and post-graduate training in pharmacology, toxicology and biochemistry at both Indian and US institutions (Case Wester Reserve University, Medical College of Ohio and the University of Nebraska) and is a Diplomate and Board Certified in Toxicology from the American Board of Toxicology Inc since 1992. Dixit is an accomplished executive, inventor and scientist with over 30 years of success, working with top biotechnology and pharmaceutical companies. In 2015, Dixit was selected by PharmaVoice as one of the 100 Most Inspiring People in the Pharmaceutical Industry. Dixit was a key contributor to the development and approval of ten blockbuster pharmaceuticals to the market. Currently Editor-in-Chief of Toxicology Mechanisms and Methods, and Associate Editor of Toxicology Applied Pharmacology and the Journal of Toxicology and Environmental Health—Dixit has published more than 80 peer-reviewed papers and delivered over 130 invited lectures, presentations and workshops.
Why is Annals of Medicine the Best Publication for Your Research?
Fully open access, general medical journal publishing articles under a CC BY license, allowing maximum sharing and reuse of articles to our international readership;
Publishing all scientifically valid research, including reporting of negative and null data, from translational to clinical research in all disciplines and therapy areas;
Led by an international editorial team of subject experts who ensure a constructive and rigorous peer review process;
Your research is promoted via a tailored, multi-channel approach to maximize visibility, readership and impact.
